daunorubicin has been researched along with kt 5720 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galski, H; Lazarovici, P; Nagler, A; Sivan, H | 1 |
| Mahadevan, D | 1 |
2 other study(ies) available for daunorubicin and kt 5720
| Article | Year |
|---|---|
In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Carbazoles; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Transgenic; Multiple Myeloma; Pyrroles | 2006 |
Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Carbazoles; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Transgenic; Multiple Myeloma; Pyrroles | 2006 |